Proportional hazards general linear model analysis on NRM, OS, and EFS
| . | NRM . | P . | OS . | P . | EFS . | P . |
|---|---|---|---|---|---|---|
| No. of patients | 266 total patients | — | 266 total patients/253 patients surviving at day 100 | — | 266 total patients/238 patients surviving free of events at day 100 | — |
| Covariates* | ||||||
| Disease stage† | 1.7 (1.2-2.4) | < .002 | 1.6 (1.3-2.0) | < .0001 | 1.7 (1.3-2.0) | < .0001 |
| 1.6 (1.2-2.0) | < .0001 | 1.6 (1.2-2.0) | < .0002 | |||
| Acute GVHD† | 3.8 (1.6-9.3) | < .003 | 2.1 (1.3-3.2) | < .002 | 1.9 (1.2-2.9) | < .003 |
| 1.8 (1.1-2.8) | < .01 | 2.0 (1.2-3.3) | < .007 | |||
| Chronic GVHD† | — | NS | 0.2 (0.1-0.4) | < .0001 | 0.2 (0.1-0.4) | < .0001 |
| 0.3 (0.2-0.4) | < .0001 | 0.3 (0.2-0.4) | < .0001 | |||
| HCMV pp65-antigenemia† | — | NS | 0.4 (0.3-0.7) | < .0008 | 0.4 (0.2-0.6) | < .0001 |
| 0.5 (0.3-0.9) | < .01 | 0.4 (0.2-0.7) | < .0008 |
| . | NRM . | P . | OS . | P . | EFS . | P . |
|---|---|---|---|---|---|---|
| No. of patients | 266 total patients | — | 266 total patients/253 patients surviving at day 100 | — | 266 total patients/238 patients surviving free of events at day 100 | — |
| Covariates* | ||||||
| Disease stage† | 1.7 (1.2-2.4) | < .002 | 1.6 (1.3-2.0) | < .0001 | 1.7 (1.3-2.0) | < .0001 |
| 1.6 (1.2-2.0) | < .0001 | 1.6 (1.2-2.0) | < .0002 | |||
| Acute GVHD† | 3.8 (1.6-9.3) | < .003 | 2.1 (1.3-3.2) | < .002 | 1.9 (1.2-2.9) | < .003 |
| 1.8 (1.1-2.8) | < .01 | 2.0 (1.2-3.3) | < .007 | |||
| Chronic GVHD† | — | NS | 0.2 (0.1-0.4) | < .0001 | 0.2 (0.1-0.4) | < .0001 |
| 0.3 (0.2-0.4) | < .0001 | 0.3 (0.2-0.4) | < .0001 | |||
| HCMV pp65-antigenemia† | — | NS | 0.4 (0.3-0.7) | < .0008 | 0.4 (0.2-0.6) | < .0001 |
| 0.5 (0.3-0.9) | < .01 | 0.4 (0.2-0.7) | < .0008 |
— indicates not applicable; and NS, not significant (P ≥ .01).
Proportional hazards general linear models with forward and backward selection of covariates; time-dependent covariates: time intervals to grades II to IV acute GVHD, chronic GVHD, and HCMV pp65-antigenemia; and further covariates included in all PHGLM analyses: stratified patient age; patient/donor sex match; pretransplantation risk score; donor type; graft source; pretransplantation HCMV donor and recipient serology; and disease genetic group.
Hazard ratio (HR) and 95% CI after adjustment for all significant (P < .01) covariates in the final models.